Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI and UCB end their commercial relationship with regards to Cimzia
Mon, 03/09/2012 - 16:45
0 min
Download related document
Select rating
Give ROVI and UCB end their commercial relationship with regards to Cimzia 1/5
Give ROVI and UCB end their commercial relationship with regards to Cimzia 2/5
Give ROVI and UCB end their commercial relationship with regards to Cimzia 3/5
Give ROVI and UCB end their commercial relationship with regards to Cimzia 4/5
Give ROVI and UCB end their commercial relationship with regards to Cimzia 5/5
No votes yet
Related
Press release for the first quarter of 2017
0 min
21/04/2017
Presentation of results for the first quarter of 2017
0 min
21/04/2017
The biosimilar Enoxaparin, a great opportunity for ROVI
“La historia de ROVI está unida a las heparinas desde nuestros inicios, por lo que este biosimilar de enoxaparina es una evolución lógica...
1 min
13/03/2017
See More
Email
Facebook
Twitter
LinkedIn